Gosogliptin is a potent, selective DPP-4 inhibitor that elevates active incretin levels (GLP-1, GIP) to enhance glucose-dependent insulin secretion. It is used in research for studying type 2 diabetes mechanisms and has demonstrated efficacy in both in vitro enzymatic assays and in vivo animal models.